Related Experiment Video
Updated: Aug 5, 2025

08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.3K
The Next Frontier in Sarcoma: Molecular Pathways and Associated Targeted Therapies
1Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Cancers
|March 29, 2023
Summary
Soft tissue sarcomas (STS) are rare cancers with diverse subtypes. Understanding their molecular pathways is key to developing targeted therapies and overcoming challenges with conventional chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Soft tissue sarcomas (STS) represent a rare and heterogeneous group of mesenchymal neoplasms, comprising over 150 histological subtypes.
- Conventional chemotherapy offers modest efficacy for STS, presenting significant treatment challenges due to disease complexity and heterogeneity.
Purpose of the Study:
- To review the current understanding of STS tumorigenesis, focusing on molecular pathways.
- To discuss emerging targeted therapies and potential new treatment avenues for STS.
Main Methods:
- Comprehensive literature review of STS tumorigenesis.
- Analysis of oncogenic pathway alterations (cell cycle, angiogenesis, NOTCH signaling, genetic rearrangements).
- Review of current and emerging targeted therapies and clinical studies.
Main Results:
- Identified key molecular pathways involved in STS initiation, metastasis, and drug resistance.
- Highlighted recent advancements in targeted therapies for specific STS subtypes.
- Discussed ongoing clinical trials for novel sarcoma treatments.
Conclusions:
- Discerning molecular pathways is crucial for advancing STS treatment.
- Targeted therapies show promise in addressing the heterogeneity and modest efficacy of conventional treatments.
- Further research into molecular pathways will guide future therapeutic strategies for sarcomagenesis.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K

